Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Interleukin-15 × Clear all
NCT01369888 2015-01-27

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 8 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡